TMEFF1 and cancer: The positive rate and high expression rate of TMEFF1 in early-stage cancer (I-II) were 76.78% (43 of 56) and 50.00% (28 of 56), respectively, which was significantly lower than those in the late stage (III-IV) (100.00% [19 of 19] and 78.95% [15 of 19]; P=0.021 and 0.027, respectively).